Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT00864 in Mild Alzheimer's Disease (PLEODIAL-II)
NCT02361242Phase 2Completed
- Sponsor
- Pharnext
- Start
- Jun 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acamprosate + baclofen in Alzheimer's disease (AD), sponsored by Pharnext. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 24 weeks. Started Jun 2013; status: completed.
02
Drugs
acamprosate + baclofen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02361242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361242.